ImmunoClin Ltd. to Provide Contract Research Organization (CRO) Services for Crotoxin Phase I Part II Clinical Trials for Spotlight Innovation Subsidiary Celtic Biotech
Marketwired - Wed May 20, 11:40AM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces today that ImmunoClin Ltd. will act as its Contract Research Organization for its subsidiary Celtic Biotech Iowa, Inc.'s Part II of its Phase I clinical trial, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. (a subsidiary of ImmunoClin Corporation, IMCL) will manage and coordinate all aspects of the clinical trial on behalf of Celtic Biotech including protocol preparation, monitoring, project management, and regulatory reporting.
Subsidiary of ImmunoClin Corporation (IMCL) receives controlled drug license in the United Kingdom
PR Newswire - Thu Apr 02, 11:51AM CDT
ImmunoClin Corporation (OTC Markets: IMCL), a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory.
ImmunoClin Corporation (IMCL) Relocates European Headquarters and Laboratories to London, UK
PR Newswire - Tue Mar 10, 9:29AM CDT
ImmunoClin Corporation (OTC Markets: IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The Company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders. ImmunoClin Corporation has completed the strategic relocation of its European headquarters from France to the United Kingdom and has established its laboratories at the London Bioscience Innovation Centre (LBIC) in Central London. ImmunoClin's corporate headquarters continue to be based in Washington, DC, USA.
Strategic Review of Corn Starch Industry & Markets - Starch, Sweeteners, Bioprocessing & Co-Products 2014
PR Newswire Europe - Wed Nov 26, 8:01PM CST
Research and Markets ( http://www.researchandmarkets.com/research/vk...ic_review) has announced the addition of the "Strategic Review of Corn Starch Industry & Markets - Starch, Sweeteners, Bioprocessing & Co-Products 2014" [http://www.researchandmarkets.com/research/vk8bgt/strategic_review ] report to their offering.
Cannabis Science Announces Corporate Changes, Appointing Raymond Dabney As President And CEO And Dr. Dorothy Bray As Scientific Advisory Board Chair And Clinical Development Consultant
PR Newswire - Thu Nov 06, 5:45AM CST
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that some major corporate changes are taking place, allowing the Company to better position itself to face the continuing evolution of the industry and ongoing and incoming projects and initiatives.
Cannabis Science, Inc. (CBIS) Signs Drug Development and Laboratory Services Agreement with ImmunoClin Corporation (IMCL); Collaboration to Advance Clinical Studies and Formulations of the Company's Proprietary Cannabinoid Based Products
PR Newswire - Mon Sep 29, 12:56PM CDT
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, has entered into a laboratory services agreement with ImmunoClin Corporation (IMCL) through its wholly-owned UK subsidiary, ImmunoClin Ltd., a healthcare company with over thirteen years' experience in providing premiere laboratory and related pre-clinical and clinical research services on a commercial scale.
Kadmon Corporation Announces the Appointment of Dr. Harlan W. Waksal as President and Chief Executive Officer and Dr. Samuel Waksal as Chief of Innovation, Science and Strategy
Marketwire - Wed Sep 24, 2:00PM CDT
Kadmon Corporation, LLC announces today that Harlan W. Waksal, M.D., has joined the Company as its President and Chief Executive Officer after serving as a member of the Company's Board of Managers since April 2014. Dr. Harlan Waksal replaces Samuel D. Waksal, Ph.D., one of the founders of Kadmon, in the Chief Executive role. Dr. Samuel Waksal remains with the Company as Chief of Innovation, Science and Strategy.
LLY: 88.29 (+0.81)
ImmunoClin Corporation (IMCL) Announces the Appointment of Infectious Disease Expert, Dr. Heinz Ellerbrok, to the Company's Scientific Advisory Board
PR Newswire - Tue Aug 05, 10:22AM CDT
ImmunoClin Corporation (OTCBB: IMCL) is a U.S. healthcare company specializing in personalized medicine, novel anti-infectious, anti-inflammatory therapies and innovative nutritional formulations. Today, the Company is pleased to announce the appointment of Dr. Heinz Ellerbrok to its Scientific Advisory Board.
ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC
PR Newswire - Tue Jul 29, 8:21AM CDT
ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders. As of August 1, 2014, ImmunoClin Corporation will complete the strategic relocation of its corporate headquarters to Washington, D.C., a key center of North American healthcare and biotechnology industries and related governmental agencies. In addition, the Company's chief operating officer, general counsel, and director, Chad S. Johnson, Esq., who will oversee the principal corporate office, is a decades-long D.C. resident.